GlassScriptPhysician profile
Dhruv Bansal
NPI 1023296209
$78,835.50
in general payments reported to CMS, 2019-2025
17 companies · $73K in 2025
The $73K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $99.99 · 2022: $296 · 2023: $166 · 2024: $4,879 · 2025: $73K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Consulting Fee: $23K · Travel and Lodging: $6,598 · Food and Beverage: $2,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,065.00 |
| Consulting Fee | $22,600.75 |
| Travel and Lodging | $6,597.83 |
| Food and Beverage | $2,991.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $65,451.35 | 2024-2025 | Rybrevant, Carvykti |
| Astrazeneca Pharmaceuticals LP | $9,542.31 | 2023-2025 | Tagrisso, Datroway |
| Janssen Global Services, LLC | $1,462.50 | 2025 | Rybrevant |
| Daiichi Sankyo INC. | $1,153.70 | 2025 | Datroway |
| Dendreon Pharmaceuticals LLC | $235.88 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $168.91 | 2025 | Rybrevant |
| Genentech, INC. | $162.05 | 2025 | Tecentriq, Tecentriq Hybreza |
| Novartis Pharmaceuticals Corporation | $138.78 | 2022 | |
| Medtronic, INC. | $138.59 | 2025 | Percept PC Brainsense |
| Amgen INC. | $99.99 | 2020 | |
| Abbvie INC. | $95.00 | 2019 | |
| Genentech USA, INC. | $77.03 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $39.29 | 2019-2023 | Imbruvica |
| Pacira Pharmaceuticals Incorporated | $27.48 | 2025 | Exparel |
| Merck Sharp & Dohme LLC | $22.26 | 2025 | Bridion |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $20.38 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhruv Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.